Scientists have found an existing gene test frequently used on the NHS can also shed light on whether a bowel cancer patient will respond positively or negatively to chemotherapy.
Researchers from The Institute of Cancer Research, Imperial College London and the Netherlands Cancer Institute have found the KRAS test can have use beyond its current function of predicting how patients will react to cancer drug cetuximab.
